Intellia Therapeutics, Inc. (NTLA)
NASDAQ • Healthcare
Last close at October 23, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 5
in 11 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Next report — what to expect
Intellia Therapeutics, Inc. (NTLA) reports next on November 5, 2026. Wall Street is looking for EPS of -$0.801 on revenue of $9.7 million. For trailing context, revenue fell -46.2% year over year last quarter. Intellia has beaten EPS in 7 of its 8 most recent quarters.
About Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. is a NASDAQ-listed Biotechnology company developing genomic medicines through genome editing, with both in vivo and ex vivo programs. In FY2025, the company recorded $67.7 million in revenue. Intellia operates in the healthcare sector and centers its platform on CRISPR/Cas9-based therapeutic development.
Today's Snapshot
The day ended with NTLA slightly higher at 11.21, while its sector was weaker. Shares changed hands at about two-thirds of its usual level. Intellia Therapeutics appointed a new chief medical officer.
Trading Volume
Below 10d avg (4.6M)
3.2M
vs S&P 500 Today
Outperforming Market
+0.97%
Updated: October 23, 2026 at 20:12 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$11.60 - $12.45Sell
- RSI (14)41.76Neutral
- Stochastic %K (14, 3, 3)21.79Neutral
- MACD Level (12, 26)-0.23Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.